2013
DOI: 10.1038/nature12202
|View full text |Cite
|
Sign up to set email alerts
|

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

Abstract: Influenza viruses pose a significant threat to the public and are a burden on global health systems. Each year, influenza vaccines must be rapidly produced to match circulating viruses, a process constrained by dated technology and vulnerable to unexpected strains emerging from humans and animal reservoirs. Here we use knowledge of protein structure to design self-assembling nanoparticles that elicit broader and more potent immunity than traditional influenza vaccines. The viral haemagglutinin was genetically … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

19
789
0
2

Year Published

2015
2015
2022
2022

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 744 publications
(869 citation statements)
references
References 32 publications
19
789
0
2
Order By: Relevance
“…For example, some studies [39][40][41] suggest a key role is having different HA heads in the prime vaccination and subsequent boosts, whereas other studies successfully boosted cross-reactive stem-specific antibodies using a homologous HA boost [37,38]. Our models predict that using the same or different HA head is not a critical factor in the boosting of stem-specific antibodies following immunization with HA (compare right panels in electronic supplementary material, figure S3), and we have identified the two key parameters (pre-existing immunity and the antigen dose) for boosting cross-reactive stem-specific immunity.…”
Section: Implication For Vaccinationmentioning
confidence: 99%
See 1 more Smart Citation
“…For example, some studies [39][40][41] suggest a key role is having different HA heads in the prime vaccination and subsequent boosts, whereas other studies successfully boosted cross-reactive stem-specific antibodies using a homologous HA boost [37,38]. Our models predict that using the same or different HA head is not a critical factor in the boosting of stem-specific antibodies following immunization with HA (compare right panels in electronic supplementary material, figure S3), and we have identified the two key parameters (pre-existing immunity and the antigen dose) for boosting cross-reactive stem-specific immunity.…”
Section: Implication For Vaccinationmentioning
confidence: 99%
“…Immune sera from these mice also neutralized other group 1 influenza viruses such as H2N2 and H5N1 [37]. A second approach used immunization of HA-nanoparticles containing HA from H1N1 and generated much higher responses to both matched and unmatched H1N1 strains than immunization with TIV; this approach also showed greater control of viral load following challenge in ferrets [38]. A third strategy was to use sequential vaccinations with chimeric HA that have a conserved stem region but head regions from different subtypes [39][40][41].…”
Section: Implication For Vaccinationmentioning
confidence: 99%
“…In some cases, such as influenza virus (Kanekiyo et al , 2013; Krammer & Palese, 2014; Yassine et al , 2015) or human immunodeficiency virus (HIV) (Kwong et al , 2013), a universal vaccine is sought to overcome strain variability so that a single immunogen designed to reorient the antibody response toward relatively conserved antigenic regions would protect against infections with highly divergent antigenic variants. In other cases, the aim is to develop vaccines that will cross‐protect against related viruses from the same family, such as the Flaviviridae Zika and dengue viruses (Barba‐Spaeth et al , 2016).…”
Section: Discussionmentioning
confidence: 99%
“…This can create particles with immunisation properties to use as more gentle vaccination agents [138].…”
Section: Delivery Of Anticancer Drugsmentioning
confidence: 99%